Press release
Tardive Dyskinesia Therapeutics Market Overview, Key Trends, and Major Player Analysis
Tardive Dyskinesia Therapeutics Market
Forecasted Growth and Market Size of Tardive Dyskinesia Therapeutics
The tardive dyskinesia therapeutics market is anticipated to experience solid growth, reaching a value of $4.39 billion by 2030. This projection reflects a compound annual growth rate (CAGR) of 7.0%. Factors contributing to this expansion include the development of new drugs targeting tardive dyskinesia, heightened research and development efforts in neurological disorders, a rising preference for homecare treatment models, the growth of specialty treatment centers, enhanced patient monitoring technologies, and innovations in digital therapeutics. Important trends shaping the market during the forecast period are the increasing adoption of deutetrabenazine and valbenazine, a growing emphasis on personalized neurological therapies, expansion of remote and home-based care options, greater awareness around drug-induced tardive dyskinesia, and a stronger focus on treatment safety and compliance over the long term.
Download a free sample of the tardive dyskinesia therapeutics market sample:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24718&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR
Leading Firms Driving the Tardive Dyskinesia Therapeutics Market
Several prominent companies currently dominate the tardive dyskinesia therapeutics sector. Key players include Neurocrine Biosciences Inc., Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Lundbeck A/S, Mitsubishi Tanabe Pharma Corporation, AbbVie Inc., Pfizer Inc., Novartis AG, Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Zydus Lifesciences Ltd., Lupin Limited, Amneal Pharmaceuticals Inc., Lannett Company Inc., Alembic Pharmaceuticals Ltd., Aurobindo Pharma Ltd., Hikma Pharmaceuticals PLC, Accord Healthcare Ltd., Cipla Ltd., Glenmark Pharmaceuticals Ltd., Sunovion Pharmaceuticals Inc., Indivior PLC, Viatris Inc., Alkem Laboratories Ltd., Intas Pharmaceuticals Ltd., Som Biotech Ltd., Addex Therapeutics Ltd., Luye Pharma Group Ltd., Apotex Inc., Sandoz Group AG, Torrent Pharmaceuticals Ltd., Jubilant Pharmova Ltd., Taro Pharmaceutical Industries Ltd., and Cadila Pharmaceuticals Ltd.
Collaborative Efforts Enhancing Market Reach
In a notable collaboration announced in February 2024, Teva Pharmaceutical Industries Limited, an Israel-based biopharmaceutical firm, partnered with Jiangsu Nhwa Pharmaceutical Co. Ltd. to promote and distribute Teva's AUSTEDO in China. This alliance leverages Jiangsu Nhwa's strong foothold in China's neuropsychiatric health sector to improve patient access to AUSTEDO, which is the first VMAT2 inhibitor approved by the U.S. FDA for treating tardive dyskinesia and chorea associated with Huntington's disease in adults. Jiangsu Nhwa Pharmaceutical Co. Ltd. is a major pharmaceutical company based in China.
View the full tardive dyskinesia therapeutics market report:
https://www.thebusinessresearchcompany.com/report/tardive-dyskinesia-therapeutics-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR
Innovations and Trends Positively Affecting Market Growth
Companies in the tardive dyskinesia therapeutics arena are focusing on creating advanced treatment products, particularly once-daily dosing options that help maintain steady drug levels in patients. These once-daily therapies simplify treatment regimens and improve adherence. For example, in May 2024, Teva Pharmaceutical Industries Limited received FDA approval for AUSTEDO XR tablets for adults with tardive dyskinesia and Huntington's disease chorea. This new formulation provides effective management of involuntary movements with the convenience of a single daily pill, backed by clinical trials demonstrating its therapeutic benefits. The medication is available in four different strengths: 30 mg, 36 mg, 42 mg, and 48 mg.
Breakdown of the Tardive Dyskinesia Therapeutics Market
This market is segmented in various ways to provide detailed insights:
1) By Drug: Deutetrabenazine, Valbenazine, and Other Drugs
2) By Product Type: Solid Dosage Forms, Tablets, Capsules, and Liquid Dosage Form
3) By Application: Antipsychotic-Induced Tardive Dyskinesia, Other Drug-Induced Tardive Dyskinesia, and Idiopathic Tardive Dyskinesia
4) By End-User: Hospitals, Clinics, Specialty Treatment Centers, and Homecare Settings
Further subsegments include:
- For Deutetrabenazine: Dosage Forms, Line of Therapy, Distribution Channel
- For Valbenazine: Dosage Forms, Patient Age Group, Distribution Channel
- For Other Drugs: Drug Class or Type, Dosage Forms, Treatment Duration
These classifications help map out the market comprehensively, reflecting the diverse approaches and needs within the tardive dyskinesia therapeutics landscape.
Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Tardive Dyskinesia Therapeutics Market Overview, Key Trends, and Major Player Analysis here
News-ID: 4501412 • Views: …
More Releases from The Business Research Company
Thin Film Drug Manufacturing Market Overview: Major Segments, Strategic Developm …
The thin film drug manufacturing sector is poised for significant expansion as pharmaceutical innovations and patient-centric drug delivery methods gain traction. Advancements in technology and growing healthcare needs are driving this market forward, setting the stage for notable growth in the coming years. Let's explore the market's current size, key players, emerging trends, and detailed segment analysis to understand its future trajectory.
Projected Growth and Market Size of Thin Film Drug…
In-Depth Examination of Segments, Industry Trends, and Leading Competitors in th …
The therapeutic BCG vaccines market is gaining significant momentum as it moves toward 2030. With advancements in medical technology and a growing emphasis on personalized treatments, this sector is positioned for substantial expansion. Below, we explore the market's size projections, key players, emerging trends, and the major segments shaping its development.
Projected Market Growth and Size of the Therapeutic BCG Vaccines Market
The therapeutic BCG vaccines market is anticipated to…
Analysis of Market Segments and Major Growth Areas in the Testosterone Cypionate …
The Testosterone Cypionate API market is poised for significant expansion in the coming years as demand for hormone therapies and specialized pharmaceutical ingredients continues to rise. This growth reflects broader trends in healthcare and pharmaceutical manufacturing, highlighting emerging opportunities and evolving industry dynamics.
Expected Market Size and Growth Rate for Testosterone Cypionate API
The market for testosterone cypionate API is projected to experience rapid growth, reaching a value of $6.38…
Key Players and Market Competition in the Temperature-Stable Messenger Ribonucle …
The temperature-stable messenger ribonucleic acid (mRNA) vial market is poised for substantial expansion over the next several years. As the pharmaceutical and biotech sectors advance, demand for stable and accessible mRNA therapies and vaccines continues to rise, signaling a promising outlook for this specialized market.
Projected Market Growth of the Temperature-Stable mRNA Vial Market Through 2030
The market for temperature-stable mRNA vials is expected to experience rapid growth, reaching a…
More Releases for Pharma
Schizophrenia Market: Expanding Revenue Landscape to 2034 - DelveInsight | Teva …
The Key Schizophrenia Companies in the market inlclude - Teva Pharmaceutical Industries, Royalty Pharma, MedinCell, Sumitomo Pharma, Otsuka Pharmaceuticals, Reviva Pharmaceuticals, Minerva Neurosciences, Mitsubishi Tanabe Pharma, Lundbeck, Intra-cellular Therapies, Sumitomo Pharma, Otsuka Pharma, Reviva Pharmaceuticals, and others.
DelveInsight's report "Schizophrenia Market Insights, Epidemiology, and Market Forecast-2034" provides a comprehensive analysis of the Schizophrenia landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the…
Dacarbazine Market Size, Share and Forecast By Key Players-Lingnan Pharma, Ruiyi …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Dacarbazine market is anticipated to grow at a compound annual growth rate (CAGR) of 14.63% between 2024 and 2031. The market is expected to grow to USD 25.32 Billion by 2024. The valuation is expected to reach USD 65.84 Billion by 2031.
The Dacarbazine market is projected to witness significant growth in the coming years, driven by increasing…
Dacarbazine Market Size, Share and Forecast By Key Players-Lingnan Pharma, Ruiyi …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Dacarbazine market is anticipated to grow at a compound annual growth rate (CAGR) of 14.63% between 2024 and 2031. The market is expected to grow to USD 25.32 Billion by 2024. The valuation is expected to reach USD 65.84 Billion by 2031.
The dacarbazine market is experiencing steady growth, driven by the rising incidence of cancer globally. As…
Epilepsy Pipeline Assessment 2024: Therapies, Clinical Trials, and Market Insigh …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Epilepsy pipeline constitutes 75+ key companies continuously working towards developing 90+ Epilepsy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Epilepsy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the…
Global Indomethacin Market Seeking Excellent Growth by 2028 | Ratiopharm, Merck, …
"IBI has published a report entitled Global Indomethacin Market Research Report which provides comprehensive data on emerging trends, market drivers, growth opportunities, and barriers that could change the dynamics of the industry market. It provides an in-depth analysis of market segments which includes the product, application, and competitor analysis.
Click Here To Order A Sample Copy Of Indomethacin Global Market Report : https://www.infinitybusinessinsights.com/request_sample.php?id=380382
The Indomethacin Global Market Research Report provides close monitoring…
Roxatidine Market 2020: Top Companies Analysis To Grow Healthcare Business by 20 …
Business Industry Reports Research has recently announced a report on Global Roxatidine Market based on the Category Industry. The Roxatidine Market report emphasizes various key aspects, which include growth drivers, restraints, opportunities and recent market trends for the forecast period 2020-2024.
Global Roxatidine Market overview:
Business Industry Reports Analyst covers the Major Players data, including: shipment, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the…
